

Contents

List of Contributors XVII

Preface XXIII

1	Proteins Separation and Purification by Expanded Bed Adsorption and Simulated Moving Bed Technology	1
	<i>Ping Li, Pedro Ferreira Gomes, José M. Loureiro, and Alirio E. Rodrigues</i>	
1.1	Introduction	1
1.2	Protein Capture by Expanded Bed Technology	3
1.2.1	Adsorbent Materials	3
1.2.2	Expanded Bed Adsorption/Desorption of Protein	10
1.2.3	Modeling of the Expanded Bed	13
1.3	Proteins Separation and Purification by Salt Gradient Ion Exchange SMB	15
1.3.1	Adsorption Isotherms and Kinetics of BSA and Myoglobin on Ion Exchange Resins	16
1.3.2	Salt Gradient Formation and Process Design for IE-SMB Chromatography	20
1.3.3	Separation Region of Salt Gradient IE-SMB Chromatography	21
1.3.4	Proteins Separation and Purification in Salt Gradient IE-SMB with Open Loop Configuration	24
1.4	Conclusion	26
	References	27
2	BioSMB Technology as an Enabler for a Fully Continuous Disposable Biomanufacturing Platform	35
	<i>Marc Bisschops</i>	
2.1	Introduction	35
2.2	Integrated Continuous Bioprocessing	36
2.3	Multicolumn Chromatography	39

2.4	BioSMB Technology	40
2.5	Fully Disposable Continuous Processing	44
2.6	Case Studies	46
2.7	Regulatory Aspects	47
2.8	Conclusions	50
	References	51
3	Impact of Continuous Processing Techniques on Biologics Supply Chains	53
	<i>Aloke Das</i>	
3.1	Introduction	53
3.1.1	The Biologics Industry	53
3.1.2	The Biologics Value Chain	54
3.1.3	Downstream Purification Costs	54
3.2	Chromatography Techniques Used in Downstream Purification of Biomolecules	55
3.2.1	Need for Continuous Manufacturing in Downstream Purification	56
3.2.2	The Multicolumn Countercurrent Solvent Gradient Purification Chromatography System	58
3.3	Next-Generation Biologic Products – Bispecific Monoclonal Antibodies	59
3.3.1	Major Biopharma Companies and Their Interest in Bispecific Mabs	59
3.3.2	Challenges in Purification of Bispecific Monoclonal Antibodies	60
3.4	Improving the Downstream Processing of Bispecific Mabs by Introduction of MCSGP in the Value Chain	61
3.4.1	Advantages of Utilizing MCSGP Process in Bispecific Mabs Purification as Compared to Batch Chromatography	61
3.4.2	Impact of MCSGP System on Biologic Supply Chains	62
3.4.3	Impact on Patent Approval Structure of Biologic Drugs	62
3.4.3.1	For a Manufacturer Who Already has a Biologic Drug in the Market	62
3.4.3.2	For a Manufacturer Who is Developing a Biologic Drug	62
3.4.4	Impact on Big Biopharma Companies	63
3.4.5	Impact on the Chromatography Market	64
3.4.6	Limitations of the MCSGP System	64
3.5	Conclusion	64
3.6	Further Research	65
	Acknowledgments	66
3.A	Appendix/Additional Information	66
3.A.1	Regulatory Structure for Bispecific Monoclonal Antibodies	67
3.A.1.1	Regulatory Compliance Comparison between US, EU, and Emerging Economies	67
	References	68

4	Integrating Continuous and Single-Use Methods to Establish a New Downstream Processing Platform for Monoclonal Antibodies	71
	<i>Christopher Gillespie, Mikhail Kozlov, Michael Phillips, Ajish Potty, Romas Skudas, Matthew Stone, Alex Xenopoulos, Alison Dupont, Jad Jaber, and William Cataldo</i>	
4.1	Introduction	71
4.2	Harvest and Clarification	74
4.2.1	The Challenge and Technology Selection	74
4.2.1.1	Centrifugation	76
4.2.1.2	Filtration	76
4.2.1.3	Impurity Precipitation	77
4.2.2	Summary	77
4.3	Capture	78
4.3.1	Background	78
4.3.1.1	Protein A Chromatography	78
4.3.2	Chromatographic Methods	79
4.3.2.1	Slurried Bed Methods	79
4.3.2.2	Continuous Chromatography	79
4.3.3	Capture Case Studies	82
4.3.3.1	Continuous Protein A Chromatography Capture Case Study	82
4.3.3.2	Effect of Clarification Method on Protein A Performance	83
4.4	Polishing	84
4.4.1	Background	84
4.4.2	Technology Selection Strategy	86
4.4.3	Complete Flow-Through Polishing Case Study	87
4.5	Cost of Goods Analysis	89
4.5.1	Methodology	89
4.5.2	Clarification	89
4.5.3	Capture	90
4.5.4	Polishing	91
4.5.5	Overall	91
4.6	Summary	92
	References	93
5	Modeling of Protein Monomer/Aggregate Purification by Hydrophobic Interaction Chromatography: Application to Column Design and Process Optimization	97
	<i>Mark-Henry Kamga, Hae Woo Lee, Namjoon Kim, and Seongkyu Yoon</i>	
5.1	Introduction	97
5.2	Mathematical Model	99
5.2.1	The Rate-Limiting Step in the HIC Process	99
5.2.2	Dimensional Considerations	100
5.2.2.1	Adsorption Capacity vs. Concentration of Vacant Sites (q_{mi} vs. C_{vi})	100
5.2.2.2	Concentration of Protein Adsorbed on Resin (q_i vs. C_{ia})	100

5.2.3	Mathematical Model	101
5.3	Experimentation	103
5.3.1	Protein Solutions	103
5.3.2	Determination of Adsorption and Desorption Kinetic Constants	104
5.3.3	Column Chromatography	104
5.4	Results and Discussion	105
5.4.1	Kinetic Constants	105
5.4.2	Protein Denaturation	107
5.4.3	Model vs. Experimental Results	108
5.4.4	Applications	109
5.5	Conclusion	112
	Acknowledgments	112
	References	113
6	Continuous Animal Cell Perfusion Processes: The First Step Toward Integrated Continuous Biomanufacturing	115
	<i>Leda R. Castilho</i>	
6.1	Introduction	115
6.2	The Basics of Perfusion Processes	116
6.3	Cell Banking and Inoculum Development in the Context of Perfusion Processes	117
6.4	Culture Conditions	120
6.5	Cell Retention Devices	125
6.5.1	Gravitational Settlers	126
6.5.2	Centrifuges	130
6.5.3	Hydrocyclones	131
6.5.4	Acoustic (Ultrasonic) Separators	134
6.5.5	Tangential Flow-Filtration	134
6.5.6	ATF Systems	136
6.5.7	Floating Membrane Devices	138
6.5.8	Spin-Filters	138
6.5.9	Rotating Cylindrical Filters (Vortex-Flow Filters or External Spin-Filters)	140
6.5.10	Rotating Disc Filters (Controlled-Shear Filters)	141
6.6	Integrated Perfusion–Purification Processes for Continuous Biomanufacturing	142
6.7	Concluding Remarks	144
	References	145
7	Perfusion Process Design in a 2D Rocking Single-Use Bioreactor	155
	<i>Nico M.G. Oosterhuis</i>	
7.1	Introduction	155
7.2	Production Costs	155
7.3	Equipment Requirements for a Single-Use Perfusion Process	157

7.4	Testing Results Single-Use Perfusion Process	159
7.5	Simplified Seeding Process	161
7.6	Future Outlook	163
	References	163
8	Advances in the Application of Perfusion Technologies to <i>Drosophila</i> S2 Insects Cell Culture	165
	<i>Lars Poulsen and Willem A. de Jongh</i>	
8.1	Introduction	165
8.2	Case Study 1: Acoustic Separation	167
8.2.1	The Perfusion Setup (BioSep)	167
8.2.2	Results and Discussion	168
8.2.2.1	Development	168
8.2.2.2	Cell Count in the Bioreactor	168
8.2.2.3	Effects of BioSep Settings on Cell Loss and Viability	169
8.2.2.4	Controlling the Cell Concentration Through Bleed Rate Control	169
8.2.2.5	Effect of Total Dilution Rate on Culture Viability	170
8.2.2.6	Development of the Perfusion Rate Profile	170
8.2.2.7	Initial Testing of Robustness of Upstream Process in 1.5 l Fermentations	170
8.2.2.8	Scaling Up and Consistency in 4.5 l Fermentations	171
8.2.2.9	Process Scale-Up	174
8.2.3	Conclusions for Case Study 1	174
8.3	Case Study 2: ATF-Based Cell Retention	176
8.3.1	ATF Technology	176
8.3.2	Methods	177
8.3.3	Results	177
8.3.3.1	Cell Counts Achieved Using Perfusion Technology	177
8.3.3.2	Effect of Feed Strategy	178
8.3.3.3	Yield Improvements Achieved Using Fed-Batch and Concentrated Perfusion	179
8.3.3.4	Protein Stability	179
8.3.4	Conclusions for Case Study 2	180
8.4	Final Remarks	181
	Acknowledgments	181
	References	181
9	Single-Use Systems Support Continuous Bioprocessing by Perfusion Culture	183
	<i>William G. Whitford</i>	
9.1	Introduction	183
9.2	Potential Advantages in Continuous Processing	187
9.2.1	Improved Product Quality	187
9.2.2	Ease in Process Development	188

9.2.3	Improved Scalability	188
9.2.4	Increased Profitability	189
9.2.5	Sustainability	190
9.3	Challenges in Adoption of Continuous Processing	190
9.4	Continuous Biomanufacturing	194
9.5	Single-Use Systems	196
9.6	Hybrid Systems	202
9.7	Perfusion Culture	203
9.8	Single-Use in Continuous Biomanufacturing	205
9.9	Roller Bottles	213
9.10	Mechanically Agitated Suspension Reactors	213
9.11	Hollow Fiber Media Exchange	214
9.12	Packed Bed Bioreactors	215
9.13	Hollow Fiber Perfusion Bioreactors	217
9.14	Continuous Flow Centrifugation	218
9.15	Acoustic Wave Separation	220
9.16	Conclusion	222
	References	222
10	Multicolumn Countercurrent Gradient Chromatography for the Purification of Biopharmaceuticals	227
	<i>Thomas Müller-Späth and Massimo Morbidelli</i>	
10.1	Introduction to Multicolumn Countercurrent Chromatography	227
10.2	Introduction to Multicolumn Simulated Moving Bed (SMB) Chromatography	230
10.3	Capture Applications	232
10.3.1	Introduction	232
10.3.2	Process Principle	234
10.3.3	Application Examples	236
10.4	Polishing Applications	237
10.4.1	Introduction	237
10.4.2	Multicolumn Countercurrent Solvent Gradient Purification Principle	239
10.4.3	Multicolumn Countercurrent Solvent Gradient Purification Process Design	242
10.4.4	Multicolumn Countercurrent Solvent Gradient Purification Case Study	243
10.5	Discovery and Development Applications	247
10.6	Scale-Up of Multicolumn Countercurrent Chromatography	249
10.7	Multicolumn Countercurrent Chromatography as Replacement for Batch Chromatography Unit Operations	249
10.8	Multicolumn Countercurrent Chromatography in Continuous Manufacturing	251
10.9	Process Analytical Tools for Multicolumn Countercurrent Processes	252
	References	253

11	Monoclonal Antibody Continuous Processing Enabled by Single Use	255
	<i>Mark Brower, Ying Hou, and David Pollard</i>	
11.1	Introduction	255
11.1.1	Single-Use Revolution to Enable Process Intensification and Continuous Processing	256
11.1.2	Principles of Continuous Multicolumn Chromatography for Biological Production (BioSMB)	260
11.2	Continuous Downstream Processing for Monoclonal Antibodies Unit Operation Development	263
11.2.1	Surge Vessels and Balancing Flows	265
11.2.2	Primary Recovery: Centrifugation and Depth Filtration	266
11.2.3	Bulk Purification: Continuous Multicolumn Chromatography – BioSMB Protein A Capture and Viral Inactivation	270
11.2.3.1	Protein A Loading Zone Optimization	271
11.2.3.2	Protein A Elution Zone Considerations	275
11.2.3.3	Viral Inactivation	277
11.2.4	Fine Purification: Flow-Through Anion Exchange Chromatography (AEX)	280
11.2.4.1	Effects of Sample Flow Rate on AEX Membrane Chromatography	281
11.2.4.2	Effect of Sample Loading Amount on AEX Membrane Chromatography	281
11.2.4.3	Scaling-Up Membrane Chromatography for Continuous Processing	283
11.2.5	Fine Purification: Continuous Multicolumn Chromatography – BioSMB Cation Exchange Chromatography	284
11.2.5.1	Cation Exchange Loading Zone Optimization	284
11.2.5.2	Cation Exchange Elution Zone Considerations	285
11.2.6	Formulation: Continuous Ultrafiltration	287
11.3	Pilot-Scale Demonstration of the Integrated Continuous Process	291
11.4	Summary	293
	References	294
12	Continuous Production of Bacteriophages	297
	<i>Aleš Podgornik, Nika Janež, Franc Smrekar, and Matjaž Peterka</i>	
12.1	Bacteriophages	297
12.1.1	Life Cycle	299
12.1.2	Determination of Bacteriophage Properties	303
12.2	Bacteriophage Cultivation	305
12.2.1	Chemostat	306
12.2.2	Cellstat	310
12.2.3	Cellstat Productivity	314
12.2.4	Bacteriophage Selection	322
12.2.5	Technical Challenges	323

12.3	Continuous Purification of Bacteriophages	325
12.3.1	Centrifugation	326
12.3.2	Precipitation and Flocculation	326
12.3.3	Filtration	327
12.3.4	Chromatographic and Other Adsorption Methods	328
12.4	Conclusions	329
	References	329
13	Very High Cell Density in Perfusion of CHO Cells by ATF, TFF, Wave Bioreactor, and/or CellTank Technologies – Impact of Cell Density and Applications	339
	<i>Véronique Chotteau, Ye Zhang, and Marie-Francoise Clincke</i>	
13.1	Introduction	339
13.2	Equipment	340
13.3	Results and Discussion	342
13.3.1	Perfusion Using ATF or TFF in Wave-Induced Bioreactor	342
13.3.1.1	Cell Growth	342
13.3.1.2	IgG Production	344
13.3.2	Perfusion Using CellTank	346
13.3.2.1	Cell Growth	346
13.3.2.2	IgG Production	347
13.3.3	Very High Cell Density	347
13.3.4	Cryopreservation from Very High Cell Density Perfusion	350
13.4	Conclusions	353
	Acknowledgments	354
	References	354
14	Implementation of CQA (Critical Quality Attribute) Based Approach for Development of Biosimilars	357
	<i>Sanjeev K. Gupta</i>	
14.1	Background	357
14.2	Biosimilar Product Development	358
14.3	Attributes/Parameters in Biopharmaceuticals	359
14.3.1	Critical Quality Attributes	359
14.3.2	Critical Process Parameters (CPP)	359
14.3.3	The ICH Q8 “Minimal Approach” to Pharmaceutical Development	359
14.3.4	Quality-by-Design	360
14.4	Quality Attributes and Biosimilars Development	361
14.5	Quality, Safety, and Efficacy of Biosimilars	362
14.6	Implementing CQA Approach for Biosimilar Development	364
14.6.1	Identification of the CQA	364
14.6.2	CQA-Based Clone Selection and Upstream Process Development	365
14.6.3	Factors Affecting CQAs of the Biologics	366

14.6.3.1	Expression Host and Recombinant Cell Line	366
14.6.3.2	Process Related	367
14.6.4	Protein Production Host and CQA	368
14.6.4.1	Cell Line Changes and CQA	370
14.6.4.2	Host Cell Line and Clone Selection Criteria	370
14.6.5	Sequence Variants Identification by CQA	371
14.6.6	Incomplete Processing of Signal Sequences and CQA	373
14.6.7	Upstream Process Impact on Product Quality Attributes	374
14.6.7.1	Bioreactor Optimization and Scale Up	374
14.6.8	CQA in Purification and Formulation	379
14.6.8.1	Downstream Processing of Biosimilars	379
14.6.8.2	Downstream Processing and CQA	380
14.6.9	CQAs in Formulation and Stability	381
14.6.9.1	Formulation and Quality Attributes	381
14.6.9.2	Stability and Quality Attributes	382
14.7	Summary	382
	References	383
15	Automated Single-Use Centrifugation Solution for Diverse Biomanufacturing Process	385
	<i>Sunil Mehta</i>	
15.1	Introduction	385
15.2	Separation by Centrifugation	385
15.3	Separation by Filtration	386
15.4	Downstream Process Challenges of High Cell Density Cultures	386
15.5	Single-Use Centrifugation	387
15.6	kSep Technology	387
15.7	kSep System Configuration	390
15.8	Low-Shear Process	392
15.9	Perfusion	393
15.10	Concentration, Media Replacement, and Harvest of Cells	395
15.11	Continuous Harvest Clarification	397
15.12	Separation of Cells from Microcarriers	398
15.13	Summary	399
	References	399
16	The Review of Flexible Production Platforms for the Future	401
	<i>Maik W. Jornitz</i>	
16.1	Introduction	401
16.2	Today's Processing Technology Advances	402
16.2.1	Single-Use Liquid Hold and Mixing Bags	402
16.2.2	Filtration and Purification Technologies	406
16.2.3	Product and Component Transfer	413
16.2.4	Aseptic Fluid Connections and Disconnections	415
16.2.5	Single-Use Final Filling Systems	417

16.3	Todays Facility Designs	418
16.3.1	Construction and Design Types	418
16.3.2	Process Location and Flow	422
16.4	Future Processing and Facility Requirements	424
16.4.1	Upstream Technologies	424
16.4.2	Downstream Technologies	426
16.4.3	Single-Use Engineering and Design	427
16.4.4	Facilities and Process Design	428
	References	431
17	Evaluating the Economic and Operational Feasibility of Continuous Processes for Monoclonal Antibodies	433
	<i>Suzanne S. Farid, James Pollock, and Sa V. Ho</i>	
17.1	Introduction	433
17.2	Background on Continuous Processing	434
17.2.1	Perfusion Culture	434
17.2.2	Semicontinuous Chromatography	436
17.3	Tool Description	438
17.4	Case Study 1: Fed-batch Versus Perfusion Culture for Commercial mAb Production	440
17.5	Case Study 2: Semicontinuous Affinity Chromatography for Clinical and Commercial Manufacture	446
17.6	Case Study 3: Integrated Continuous Processing Flowsheets	450
17.7	Conclusions	452
	Acknowledgments	452
	References	453
18	Opportunities and Challenges for the Implementation of Continuous Processing in Biomanufacturing	457
	<i>Sadettin S. Ozturk</i>	
18.1	Introduction	457
18.2	A Brief History of Continuous Processing in Biomanufacturing	458
18.3	Opportunities for Continuous Processing in Biomanufacturing	459
18.3.1	Higher Process Yields	459
18.3.2	Higher Process Efficiencies	461
18.3.3	Compact and Flexible Facilities	461
18.3.4	Stable and Consistent Production	462
18.3.5	Better Product Quality	462
18.4	Challenges for Implementing Continuous Processing in Biomanufacturing	462
18.4.1	Process Complexity	463
18.4.1.1	Cell Retention	463
18.4.1.2	High Cell Density	466
18.4.1.3	Longer Run Times	467
18.4.2	Process Scalability in a Continuous Perfusion Process	470

18.4.2.1	Scale and Capacity Limitations	470
18.4.2.2	Process Scale-up	471
18.4.3	Process Consistency and Control	473
18.4.4	Process Characterization and Validation	474
18.4.4.1	Complexity of a Scale-down Model for a Perfusion Process	474
18.4.4.2	Process Optimization and Characterization for a Perfusion Process	475
18.4.4.3	Process Validation	475
18.5	Conclusions	476
	Acknowledgment	476
	References	476
19	The Potential Impact of Continuous Processing on the Practice and Economics of Biopharmaceutical Manufacturing	479
	<i>L. Richard Stock, Marc Bisschops, and Thomas C. Ransohoff</i>	
19.1	Introduction	479
19.2	Background (Review of Status Quo – How We Make Biopharmaceutical Products Today)	480
19.3	The Rationale for Continuous Processing	483
19.4	The Obstacles for Implementation of Continuous Processing for Biopharmaceuticals	485
19.5	The Potential Impact of Continuous Manufacturing on Process Economics	487
19.6	The Potential Impact of Continuous Processing on Biopharmaceutical Manufacturing Practices	490
19.7	Summary	492
	References	492
	Index	495

